Top Markets
#1 Black Phoenix Black Phoenix +732.34%
#2 MiL.k Alliance MiL.k Alliance +26.75%
#3 Biconomy Biconomy +25.03%
#4 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +24.00%
#5 THORChain THORChain +19.41%
#6 Wrapped STX (Velar) Wrapped STX (Velar) +15.57%
#7 Tokamak Network Tokamak Network +15.53%
#8 THORChain Yield THORChain Yield +14.29%
#9 Moolah Moolah +14.06%
#10 The Black Bull The Black Bull +12.36%
Coin of the day
Black Phoenix Black Phoenix
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Zai Lab Limited Zai Lab Limited

Zai Lab Limited

ZLAB
Classifica tra le azioni #5163
Operating primarily in Mainland China and Hong Kong, Zai Lab Limited is a... Operating primarily in Mainland China and Hong Kong, Zai Lab Limited is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative medical treatments. Their therapeutic portfolio spans oncology, autoimmune conditions, infectious diseases, and neurological disorders. Currently available products in their portfolio include Zejula, a once-daily small-molecule PARP 1/2 inhibitor; Optune, a medical device leveraging tumor treating fields; NUZYRA, an antimicrobial agent for specific acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia; and Qinlock, indicated for gastrointestinal stromal tumors. Beyond its commercial offerings, Zai Lab boasts an extensive pipeline of investigational therapies. These include Odronextamab for various B-cell lymphomas; Repotrectinib, a tyrosine kinase inhibitor targeting ROS1 and TRK pathways in both TKI-naïve and pretreated cancer patients; Margetuximab for breast and gastroesophageal cancers; Adagrasib for KRAS-G12C-mutated solid tumors like NSCLC, colorectal, and pancreatic cancers; and Bemarituzumab for gastric and gastroesophageal junction cancers. Further pipeline candidates encompass CLN-081 for EGFR exon 20 insertion NSCLC; Elzovantinib, an orally available multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab, designed to block PD-1 interactions with its ligands; ZL-2309, an orally active and selective CDC7 kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod, aimed at reducing pathogenic immunoglobulin G antibodies; ZL-1102, a human nanobody against interleukin-17A; KarXT for psychiatric and neurological conditions; ZL-2313 and ZL-2314, both investigational EGFR inhibitors targeting specific mutations; and Sulbactam/durlobactam, intended for serious infections caused by Acinetobacter. Established in 2013, Zai Lab Limited maintains its corporate headquarters in Shanghai, China.
Prezzo delle azioni
$26.03
Ultima sincronizzazione: 2026-08-26
Capitalizzazione di mercato
$2.94B
Variazione (1 giorno)
-0.55%
Variazione (1 anno)
-20.07%
Paese
CN
Scambia Zai Lab Limited (ZLAB)

Categoria

Healthcare
Storico del prezzo dell'azione per Zai Lab Limited (ZLAB)
Prezzo di chiusura più alto: $25.27 il 2026-08-01

Prezzo di chiusura più basso: $27.89 il 2017-09-01
Storico del prezzo dell'azione di Zai Lab Limited dal 2017 al 2026
Andamento annuale del prezzo dell'azione
Anno Performance
2026 (TTM) 19.83%
2025 -32.96%
2024 -1.60%
2023 -15.44%
2022 -50.77%
2021 -44.11%
2020 193.25%
2019 87.31%
2018 -9.94%
2017 0.00%
Prezzo dell'azione per aziende simili o concorrenti
Azienda Prezzo dell'azione Variazione 1a% Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $549.38 41.20%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $1.05K 47.75%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $148.35 491.02%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $122.50 -12.74%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $764.47 7.08%
CH